Morepen Laboratories Ltd

Morepen Laboratories Limited announced that its wholly owned subsidiary, Morepen RX Limited (MRX), has allotted 20,00,00,000 equity shares with a face value of Rs 10 each, totaling Rs 20,00,00,000, to the company through a rights issue. Consequently, Morepen Laboratories Limited’s shareholding in MRX has increased to 2,70,82,356 equity shares, and MRX continues to be a wholly owned subsidiary. MRX, incorporated on March 17, 2023, had a turnover of Rs 5,449.84 lakh and a net worth of Rs 47.72 lakh based on audited financial statements for the financial year ended March 31, 2026.

A Monitoring Agency report indicates mixed progress for Morepen Laboratories Limited regarding the utilization of funds raised through an issuance. While the company has largely deployed the Rs 88.83 crore initially planned for completion by March 31, 2025, and the Rs 33.97 crore slated for March 31, 2026, timelines have been extended to March 31, 2026, and March 31, 2027, respectively, raising concerns about project planning and execution. The report notes a Rs 4.55 crore transfer to the company’s current account and a remaining balance of Rs 0.09 crore, prompting a review of vendor billing processes. Despite these delays, the company has effectively utilized funds for working capital and made prudent short-term investments, and the report acknowledges flexibility in fund deployment. The agency recommends strengthening project management, improving internal oversight, and enhancing transparency with investors.

Morepen Laboratories Ltd share price ticked higher by 1.19% to Rs 57.68 after the company's net profit soared by 258.92% to Rs 56.35 crore, while revenue from operations gained 17.62% to Rs 570.13 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.75 lakh crore, rising 5.95%. It has improved by 1.51% over last one week and advanced by 11.59% in last one month while the market capitalization of Morepen Laboratories Ltd has marginally improved by 4.32% and 32.41% in the same period respectively. Profit before tax (PBT) of Morepen Laboratories Ltd stood at Rs 74.53 crore in Q2 FY26, jumping 380.22% year-on-year, and surging by 220.01% quarter-on-quarter. EBITDA came in at Rs 77 crore, rallying 291.30% YoY and expanding by 383.80% sequentially. Total expenses inched up 6.42% to Rs 495.94 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 328.38 crore, increasing 13.01% YoY, while employee benefits expense was at Rs 62.44 crore, easing 6.26% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 7.17% to Rs 1811.58 crore, while net profit saw a strong growth of 22.15% to Rs 118.02 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 13917% to Rs 155.71 crore, and PBT registered a growth of 14.54% to Rs 155.11 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 32.06 crore in FY26, as against Rs 73.37 crore in FY25. Morepen Laboratories Ltd slipped 0.14% in last one year, outperforming the benchmark BSE Sensex which has softened by 2.94% during the same period.

Morepen Laboratories Limited announced its highest-ever quarterly revenue of Rs 575.31 crore and earnings for the quarter ended June 30, 2026, alongside a 207% increase in EBITDA and a 394% rise in profit after tax. The company’s CDMO mandate, valued at Rs 825 crore, has entered full-scale commercialization, with Rs 58 crore in commercial dispatches completed during the quarter, supported by a 31% growth in the API business and 19% growth in the medical devices business.

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 4 August 2026.

Morepen Laboratories today issued an update on its recently announced Rs 825 crore CDMO mandate. The first commercial dispatch, valued at approximately Rs 50 crore, has already been completed by the company under the program during Q1FY2026-27. This marks the successful transition of the mandate from validation and qualification stage to commercial execution stage. Having dispatched the first batch under the CDMO mandate, Morepen expects to scale the program further in the coming quarter, with additional supplies of approximately Rs 225 crore expected during Q2FY2026-27, subject to customer schedules and regulatory/commercial requirements. The Company continues to strengthen its manufacturing infrastructure to support larger CDMO opportunities. Total reactor capacity is expected to reach approximately 600 KL by the end of Q2, followed by further expansion toward 800 KL and 1,000 KL in subsequent phases.

Morepen Laboratories announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 0.2 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Net profit of Morepen Laboratories declined 22.54% to Rs 15.74 crore in the quarter ended March 2026 as against Rs 20.32 crore during the previous quarter ended March 2025. Sales rose 4.05% to Rs 484.72 crore in the quarter ended March 2026 as against Rs 465.85 crore during the previous quarter ended March 2025. For the full year,net profit declined 19.61% to Rs 94.88 crore in the year ended March 2026 as against Rs 118.02 crore during the previous year ended March 2025. Sales declined 0.33% to Rs 1805.69 crore in the year ended March 2026 as against Rs 1811.58 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales484.72465.85 4 1805.691811.58 0 OPM %5.049.07 -6.969.61 - PBDT29.0342.18 -31 130.52184.09 -29 PBT23.2925.71 -9 94.09155.11 -39 NP15.7420.32 -23 94.88118.02 -20 Powered by Capital Market - Live

Morepen Laboratories has revised the meeting of the Board of Directors which was scheduled to be held on 22 May 2026. The meeting will now be held on 26 May 2026.

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 22 May 2026.